Rxrx stock forecast.

NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ... Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ...Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ...

Wall Street is abuzz with the news of Nvidia’s $50 million investment in Recursion Pharmaceuticals (NASDAQ:RXRX). The biotech company’s stock surged over 120% following the announcement ...Find the latest RxSight, Inc. (RXST) stock quote, history, news and other vital information to help you with your stock trading and investing.Oct 11, 2023 · On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ...

30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price.

Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low.Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.Recursion lost $65.3 million compared to a loss of $56 million in the same period a year ago, and said it had $473.1 million in cash. Jim Halley has no position in any of the stocks mentioned. The ...Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

The 23andMe Holding Co. stock forecast for tomorrow is $ 0.786773, which would represent a -1.46% loss compared to the current price. In the next week, the price of ME is expected to decrease by -7.39% and hit $ 0.739421. As far as the long-term 23andMe Holding Co. stock forecast is concerned, here’s what our predictions are currently suggesting.

Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Three Fool.com healthcare contributors like Vertex Pharmaceuticals ( VRTX 0.22%), Repligen ( RGEN -2.06%), and Recursion Pharmaceuticals ( RXRX -0.69%). Here's why they believe these three stocks ...Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts.The consensus statutory numbers ...

Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.The US$14.13 analyst price target for RXRX is 3.5% less than our ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting ...Current. -$0.35. 1 Month Ago. -$0.35. 3 Months Ago. -$0.32. Recursion Pharmaceuticals Inc. analyst estimates, including RXRX earnings per share estimates and analyst recommendations.

All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.

Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis. Nov 28, 2023 · According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy. Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.Company Description. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.Before the stock market opened, RXRX stock had catapulted more than 130%. Nvidia stock rose 3.5% to 439.02. Recursion has a searchable data set spanning biology and chemistry. The company says its ...Nov 13, 2023 · Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years. As of Monday, August 07, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 11.05%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ...

Forecast for Fri 01 Sep 2023 price 7.05 RECURSION PHARMACEUTICALS INC stock price forecast for further price development up to 32.48% (time horizon: 1 day) and price target of 7.01 USD. Short-term (time horizon: 2 weeks) RECURSION PHARMACEUTICALS INC share price prediction for 2023-09-01 with daily closed price …

About the Recursion Pharmaceuticals, Inc. Class A Common Stock stock forecast. As of 2023 December 02, Saturday current price of RXRX stock is 6.910$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Recursion Pharmaceuticals stock price has been showing a declining tendency so we …Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX. The partnership ...RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Recursion ...Oct 11, 2023 · On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ... Find the latest ARK Genomic Revolution ETF (ARKG) stock quote, history, news and other vital information to help you with your stock trading and investing.Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ...Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs. Recursion Pharmaceuticals uses AI to find good leads ...Recursion Pharmaceuticals Inc Cl A stocks price quote with latest real-time prices, charts, financials, ... RXRX Related stocks. Symbol 3M %Chg ; RXRX -18.97% : Recursion Pharmaceuticals Inc Cl A: ZTS -6.96% : Zoetis Inc Cl A: TAK ... Cash Markets Overview Corn Indexes Soybean Indexes Yield Forecast Indexes.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Xerox Holdings share forecasts, stock quote and buy / sell signals below. According to present data Xerox Holdings's XRX shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ...

Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX.Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.RXRX Recursion Pharmaceuticals Forecast 2023. Check the latest RXRX quote. Read market charts, analyst ratings and a financial calendar ... Buy/Sell Daily Signals. Stocks & ETFs, MFs & FOREX. AI Trend Prediction Engine. Stocks & ETFs, MFs & FOREX. AI Pattern Search Engine. Stocks & ETFs & FOREX. AI Real Time Patterns. Stocks & …View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Instagram:https://instagram. stockappsstla stock forecastrare steel penny 1943rivian delivery estimates Recursion Pharmaceuticals uses AI and experimental biology to discover new treatments for diseases. Check out why I'm bullish on RXRX stock. maybach eqsmunicipal bonds yield 3 апр. 2023 г. ... Unity Stock New CEO Prioritizes Investors Over Stock Price. Jose Najarro ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August. liberty silver dollar coin InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 25, meaning RXRX is ranked higher by analysts than 25% of …Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast Growth